The U.S. Food and Drug Administration (FDA) has announced a delay in its decision regarding Eli Lilly’s much-anticipated Alzheimer’s drug, requesting an advisory panel review to evaluate the treatment’s efficacy and safety. This unexpected postponement adds to the uncertainty surrounding the approval process for new therapies targeting the debilitating neurological condition. The move comes as the FDA seeks further expert guidance amid ongoing debate over the drug’s clinical trial results and potential impact on patients and caregivers.
FDA Postpones Decision on Lilly Alzheimer’s Drug Citing Need for Further Expert Review
The U.S. Food and Drug Administration (FDA) has announced a delay in its decision regarding Eli Lilly’s new Alzheimer’s treatment, highlighting the…
—-
Author : Miles Cooper
Publish date : 2025-10-19 04:56:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8
